Medicus Pharma Ltd. Common Stock
MDCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.02 | -0.01 | 0.00 |
| FCF Yield | -43.84% | -45.10% | -20.67% | -6.79% |
| EV / EBITDA | -1.84 | -12.78 | -5.47 | -11.30 |
| Quality | ||||
| ROIC | -323.43% | -425.57% | 9.17% | 14.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 0.78 | 0.62 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -146.43% | -293.36% | 27.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.36 | 2.93 | -1.08 | -0.30 |
| Interest Coverage | -35.21 | -7.94 | -1.86 | -12.49 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |